encourag growth expect ci-
esrx transact continu
esrx report slight beat rev ahead ep
vs consensu estim ebitda also ahead though adjust
claim bit light vs consensu esrx increas retent
sell season compani also expect core
adjust claim growth vs prior neg estim
guid re-affirmed except core adj ebitda rais midpoint
despit result stock move predic on-going ci-
esrx transact recent revel activist investor push back ci
acquisit unpredict effect could paus momentum
regulatori uncertainti continu headwind
claim miss revenu ebitda ep esrx revenu
vs estim consensu adj ebitda
vs consensu estim adj ep vs
estim consensu guid adjust claim
y/i vs estim consensu
gm miss om adj gross margin vs estim
last year oper margin vs estim last
guidanc introduc adjust claim guid introduc
includ core vs consensu
estim adj ep guid vs estim consensu
guidanc mostli re-affirmed esrx re-affirmed adj ep
vs estim consensu share count guid
re-affirmed vs estim manag re-affirmed
total adj claim guid vs estim ebitda avail
esrx guid re-affirmed vs estim adj
ebitda guid rais vs
major chang estim stick rev/ep
estim updat estim slightli reflect beat
revenu remain intact ep increas slightli
mainli beat
express script largest pharmaci
benefit manag pbm us
medco health solut inc
analyst certif import disclosur see disclosur
announc intent acquir express script
cash/stock esrx last larg stand-alone
pbm acquisit catamaran cvss on-going
transact acquir aetna vertic integr model
offer better defens potenti threat
combin entiti drive health plan design ensur
incent in-network usag believ pbm portion
rx manag like first disrupt
believ ci good outcom esrx
new ceo cfo wont make dramat chang
potenti deal
posit commentari sell season
progress toward close acquisit ci
new ceo cfo wont make dramat chang
lose pbm share client retent improv stall
revenu
equiti incom joint ventur
interest expens
provis incom tax
amort intang asset
compani report oppenheim estim
